RAS/RAF co-mutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer

CONCLUSIONS: Co-occurring RAS/RAF alterations define a unique subtype of ERBB2 amplified CRC that has increased intratumoral heterogeneity, interlesional discordance and resistance to trastuzumab-based combinations. Further examination of trastuzumab deruxtecan in this previously understudied cohort of ERBB2 amplified CRC is warranted.PMID:38345769 | DOI:10.1158/1078-0432.CCR-23-2581

Source: Clinical Colorectal Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Harshabad Singh Pranshu Sahgal Kevin Kapner Steven M Corsello Hersh Gupta Rahul Gujrathi Yvonne Y Li Andrew D Cherniack Raquelle El Alam Joseph Kerfoot Elizabeth Andrews Annette Lee Chetan Nambiar Alison M Hannigan Joshua Remland Lauren Brais Meghan E Lea Source Type: research